Alkermes (NASDAQ:ALKS) Releases Earnings Results, Misses Estimates By $0.19 EPS

Alkermes (NASDAQ:ALKS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19), Zacks reports. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The company had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same period last year, the firm posted $0.43 EPS. The company's revenue for the quarter was down 12.6% compared to the same quarter last year. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Price Performance

Shares of ALKS opened at $31.78 on Friday. The firm has a market cap of $5.24 billion, a P/E ratio of 14.65, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39. The company has a 50 day simple moving average of $31.33 and a two-hundred day simple moving average of $30.44. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.45.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the transaction, the executive vice president now owns 57,875 shares in the company, valued at $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ALKS has been the topic of several research reports. HC Wainwright restated a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upped their price objective on Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a report on Thursday, March 27th. StockNews.com upgraded Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Royal Bank of Canada boosted their price objective on Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a research report on Friday. Finally, Robert W. Baird upped their price target on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a research report on Friday. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $38.33.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.